Original Research
Accepted on 29 Aug 2025
Bevacizumab and anlotinib combination therapy acts via HIF-1α suppression to exert synergistic anti-angiogenic and anti-tumor effects in non-small cell lung cancer
in Cancer Immunity and Immunotherapy
Original Research
Accepted on 29 Aug 2025
in Cancer Immunity and Immunotherapy
Brief Research Report
Accepted on 29 Aug 2025
in Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders
Original Research
Accepted on 29 Aug 2025
in Microbial Symbioses
Original Research
Accepted on 29 Aug 2025
in Work, Employment and Organizations
Original Research
Accepted on 29 Aug 2025
in Anxiety and Stress Disorders
Correction
Accepted on 29 Aug 2025
in Nutritional Immunology
Original Research
Accepted on 29 Aug 2025
in Speech and Language
Original Research
Accepted on 29 Aug 2025
in Movement Science
Original Research
Accepted on 29 Aug 2025
in Plant Metabolism and Chemodiversity
Original Research
Accepted on 29 Aug 2025
in Medical Sociology
Original Research
Accepted on 29 Aug 2025
in Microbial Physiology and Metabolism
Original Research
Accepted on 29 Aug 2025
in Children and Health
Original Research
Accepted on 29 Aug 2025
in Public Health Education and Promotion
Original Research
Accepted on 29 Aug 2025
in Medical Sociology
Curriculum, Instruction, and Pedagogy
Accepted on 29 Aug 2025
in Public Health Education and Promotion
Original Research
Accepted on 29 Aug 2025
in Urologic Oncology